Adverum Biotechnologies, Inc. (ADVM) Stock

About Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc. is a clinical-phase biotechnology firm primarily engaged in discovering and advancing gene therapies. The company's mission is to create innovative treatments for various eye-related conditions and uncommon illnesses. Its flagship experimental gene therapy, ADVM-022, is a potential therapy administered through a single injection into the vitreous humor of the eye. This treatment is being developed for individuals afflicted with persistent retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies maintains licensing and collaborative partnerships with institutions such as the University of California and Cornell University, as well as companies like GenSight, Lexeo, and Virovek. Established in 2006, the organization was initially named Avalanche Biotechnologies, Inc. before rebranding to Adverum Biotechnologies, Inc. in May 2016. Its headquarters are situated in Redwood City, California.

Adverum Biotechnologies, Inc. is headquartered in US.

Adverum Biotechnologies, Inc. (ADVM) stock trades at $4.36 with a market capitalization of $96.26M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.66, reflecting a net loss over the last twelve months, a negative price-to-book of -1.84, reflecting negative shareholders' equity, price-to-sales of 96.26. Over the past 52 weeks the stock has ranged between $1.78 and $6.07, and currently trades 28.2% below its 52-week high.

On profitability, Adverum Biotechnologies, Inc. generates a return on equity (ROE) of 872.77% (not meaningful, as shareholders' equity is negative), return on capital employed of -524.73%, an operating margin of -13900.00%, a net profit margin of -13100.00%.

Official website: www.adverum.com

Adverum Biotechnologies, Inc. by the numbers, 2015–2024

Between 2015 and 2024 Adverum Biotechnologies, Inc. reported revenue of $2.0M rising to $1.0M, a change of -50.0% across 10 years. Compounded, revenue has grown —% a year over five years, -50.0% over three, -75.0% over the last twelve months. Net profit fell to $-131.0M.

Operating margin went from -2062.2% in 2015 to -13915.9% in 2024, a fall of 11853.7 percentage points. The most recent net margin is -13100.00%. On a trailing twelve-month basis to Sep '25, revenue is $0 and net profit $-205.0M.

Borrowings stand at $92.0M, cash on hand is $26.1M, cash from operations was $-92.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -105.0% over five years, and was -184.5% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Adverum Biotechnologies, Inc. (ADVM) — frequently asked questions